← Back to Screener
Aquestive Therapeutics, Inc. Common Stock (AQST)
Price$4.26
Favorite Metrics
Price vs S&P 500 (26W)-35.60%
Price vs S&P 500 (4W)-0.35%
Market Capitalization$519.91M
All Metrics
Book Value / Share (Quarterly)$0.40
P/TBV (Annual)15.90x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-2.24%
Cash Flow / Share (Quarterly)$-0.43
Price vs S&P 500 (YTD)-37.01%
Gross Margin (TTM)58.35%
Net Profit Margin (TTM)-188.09%
EPS (TTM)$-0.78
10-Day Avg Trading Volume1.00M
EPS Excl Extra (TTM)$-0.78
Revenue Growth (5Y)-0.58%
EPS (Annual)$-0.78
ROI (Annual)-107.16%
Gross Margin (Annual)58.35%
Net Profit Margin (5Y Avg)-106.64%
Cash / Share (Quarterly)$0.99
Revenue Growth QoQ (YoY)9.67%
ROA (Last FY)-52.23%
Revenue Growth TTM (YoY)-22.61%
EBITD / Share (TTM)$-0.71
Operating Margin (TTM)-159.50%
Cash Flow / Share (Annual)$-0.43
P/B Ratio51.58x
P/B Ratio (Quarterly)15.59x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)11.79x
Net Interest Coverage (TTM)-10.98x
ROA (TTM)-64.46%
EPS Incl Extra (Annual)$-0.78
Current Ratio (Annual)3.14x
Quick Ratio (Quarterly)2.92x
3-Month Avg Trading Volume3.82M
52-Week Price Return68.25%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.40
P/S Ratio (Annual)11.67x
Asset Turnover (Annual)0.28x
52-Week High$7.55
Operating Margin (5Y Avg)-85.84%
EPS Excl Extra (Annual)$-0.78
CapEx CAGR (5Y)1.57%
26-Week Price Return-31.61%
Quick Ratio (Annual)2.92x
13-Week Price Return20.80%
Total Debt / Equity (Annual)4.68x
Current Ratio (Quarterly)3.14x
Enterprise Value$525.22
Revenue / Share Growth (5Y)-21.10%
Asset Turnover (TTM)0.34x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)3.04x
Pretax Margin (Annual)-188.09%
Cash / Share (Annual)$0.99
3-Month Return Std Dev95.01%
Gross Margin (5Y Avg)63.19%
Net Income / Employee (TTM)$-1
ROE (Last FY)-608.93%
Net Interest Coverage (Annual)-10.98x
EPS Basic Excl Extra (Annual)$-0.78
P/FCF (TTM)28.36x
Receivables Turnover (TTM)3.63x
Total Debt / Equity (Quarterly)4.68x
EPS Incl Extra (TTM)$-0.78
Receivables Turnover (Annual)3.63x
ROI (TTM)-47.80%
P/S Ratio (TTM)11.67x
Pretax Margin (5Y Avg)-106.55%
Revenue / Share (Annual)$0.42
Tangible BV / Share (Annual)$0.40
Price vs S&P 500 (52W)38.42%
Year-to-Date Return-34.37%
5-Day Price Return1.68%
EPS Normalized (Annual)$-0.78
ROA (5Y Avg)-63.72%
Net Profit Margin (Annual)-188.09%
Month-to-Date Return2.17%
Cash Flow / Share (TTM)$-0.17
EBITD / Share (Annual)$-0.71
Operating Margin (Annual)-159.50%
LT Debt / Equity (Annual)4.23x
ROI (5Y Avg)-141.26%
LT Debt / Equity (Quarterly)4.23x
EPS Basic Excl Extra (TTM)$-0.78
P/TBV (Quarterly)15.90x
P/B Ratio (Annual)15.59x
Inventory Turnover (TTM)3.04x
Pretax Margin (TTM)-188.09%
Book Value / Share (Annual)$0.40
Price vs S&P 500 (13W)20.11%
Beta1.62x
P/FCF (Annual)138.64x
Revenue / Share (TTM)$0.36
ROE (TTM)-21.76%
52-Week Low$2.12
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.20
4.20
4.20
4.20
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AQSTAquestive Therapeutics, Inc. Common Stock | 11.67x | -22.61% | 58.35% | — | $4.26 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Aquestive Therapeutics is a specialty pharmaceutical company developing and commercializing products for central nervous system disorders and severe allergic reactions. The company markets four commercial products—Suboxone, Emylif, Ondif, and Sympazan—with pipeline candidates including Libervant Buccal Film and AQST-108. Revenue is primarily generated in the United States.